(NASDAQ: NUVL) Nuvalent's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Nuvalent's revenue in 2025 is $0.On average, 8 Wall Street analysts forecast NUVL's revenue for 2026 to be $1,681,340,589, with the lowest NUVL revenue forecast at $306,445,557, and the highest NUVL revenue forecast at $4,369,553,122. On average, 6 Wall Street analysts forecast NUVL's revenue for 2027 to be $12,645,457,894, with the lowest NUVL revenue forecast at $6,464,919,685, and the highest NUVL revenue forecast at $18,225,218,600.
In 2028, NUVL is forecast to generate $34,762,462,966 in revenue, with the lowest revenue forecast at $34,290,897,332 and the highest revenue forecast at $35,492,884,965.